Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT03436862 Completed - Hodgkin Lymphoma Clinical Trials

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

Start date: May 23, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase II single-arm open-label study of nivolumab as maintenance therapy after autologous stem cell transplantation in patients with Hodgkin lymphoma at risk of relapse or progression.

NCT ID: NCT03425591 Completed - Clinical trials for Leukemia, Lymphocytic, Chronic, B-Cell

A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice

FIRE
Start date: May 11, 2016
Phase:
Study type: Observational

The purpose of this study is to describe the effectiveness of ibrutinib and to provide a description of ibrutinib therapy and the first non-ibrutinib subsequent therapy for chronic lymphocytic leukemia (CLL) and mantle-cell lymphoma (MCL).

NCT ID: NCT03424603 Completed - Multiple Myeloma Clinical Trials

Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Start date: February 22, 2018
Phase: Phase 1
Study type: Interventional

First-in-human Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-001 given intravenously every 3 weeks.

NCT ID: NCT03424122 Completed - B-cell Lymphoma Clinical Trials

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

Start date: July 2, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of parsaclisib when combined with rituximab, bendamustine and rituximab, or ibrutinib in participants with relapsed or refractory B-cell lymphoma.

NCT ID: NCT03415399 Completed - Lymphoma, B-Cell Clinical Trials

Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma

Start date: September 9, 2017
Phase: Phase 1
Study type: Interventional

This study is to determine the safety, including potential dose limiting toxicities, of ET190L1 ARTEMIS™ T cells and the duration of in vivo survival of ET190L1 ARTEMIS™ T cells in patients with relasped/refractory B-cell lymphoma. For patients with detectable disease, the study will also measure anti-tumor responses after ET190L1 ARTEMIS™ cell infusions.

NCT ID: NCT03413644 Completed - Leukemia-Lymphoma Clinical Trials

Evaluation of ClearLLab Leukemia and Lymphoma Panels

Start date: November 14, 2017
Phase:
Study type: Observational

Multi-center study of specimens from subjects presenting to the flow cytometry laboratory as part of their standard of care for hematological diseases work-up.

NCT ID: NCT03399513 Completed - Clinical trials for Diffuse Large B Cell Lymphoma

Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma

R-CHOEP-brut
Start date: May 3, 2018
Phase: Phase 2
Study type: Interventional

This study will investigate if treatment results obtained with R-CHOEP in young high-risk patients with diffuse large B-cell lymphoma can be further improved by the addition of ibrutinib to this regimen.

NCT ID: NCT03397953 Completed - Clinical trials for Anaplastic Large Cell Lymphoma

Vinorelbine for Recurrent ACLC

Start date: November 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficiency and safety of vinorelbine in the treatment of relapsed / advanced ALCL in children and adolescents.

NCT ID: NCT03384654 Completed - Clinical trials for Precursor Cell Lymphoblastic Leukemia-Lymphoma

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Start date: May 14, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of daratumumab in addition to standard chemotherapy in pediatric participants with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LL) and T-cell ALL/LL as measured by the complete response (CR) rate.

NCT ID: NCT03383055 Completed - Multiple Myeloma Clinical Trials

CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig

Start date: November 16, 2018
Phase: Phase 1
Study type: Interventional

This is a prospective, interventional study administering 2 doses of the experimental vaccine (CMV-MVA Triplex) to 20 evaluable patients (10 CMV-seropositive and 10 seronegative) undergoing autologous hematopoietic cell transplantation (HCT) for lymphoma or myeloma on days 28 and 56 post-HCT. The absolute number of adaptive NK cells (CD56dimCD57+NKG2C+) at various days will be compared.